Current Report
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): April 4, 2006
 
Xenomics, Inc.
(Exact name of registrant as specified in its charter)
 
 
Florida
  
04-3721895
  
 
(State or other jurisdiction of incorporation or organization)
  
(IRS Employer Identification No.)
  
 
 
  
 
  

 
420 Lexington Avenue, Suite 1701
  
 
New York, New York 10170
  
 
(Address of principal executive offices)
  
 
Registrant’s telephone number, including area code: (212) 297-0808
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
o
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
   
 
On April 4, 2006, the Board of Directors of Xenomics, Inc., a Florida corporation ("Xenomics"), pursuant to a regularly scheduled Board of Directors meeting appointed Colin J. Foster, a director of Xenomics to serve until the next annual meeting of the stockholders of Xenomics and/or until his successor has been duly elected and qualified.

Since December 2004, Mr. Foster has been a consultant and has been active as a board member of the University of New Haven. From April 2002 to December 2004, Mr. Foster was President and Chief Executive Officer of Bayer Pharmaceuticals Corporation, and Regional Head, North American Pharmaceuticals, part of Bayer AG. In addition, Mr. Foster was United Kingdom/Ireland Region Head, Diagnostics Division of Bayer AG from June 1999 to April 2002.
     
Item 9.01 Financial Statements and Exhibits
   
(c)  
Exhibits.
   
  99.1         Press Release dated April 5, 2006.
 
2
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated: April 7, 2006
 
     
  XENOMICS, INC.
 
 		  
 		  
 
  By:   /s/ L. David Tomei
 
 
L. David Tomei
Chief Executive Officer
 
 
3